此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Verification of Shear Wave Elastography for DEtection of Prostate Cancer

2021年4月7日 更新者:Yonsei University
  1. Objective To provide evidence that adding shear wave elastography during sono-guided prostate biopsy can increase prostate cancer detection rate and to demonstrate that shear wave elastography of the prostate can discriminate malignant lesions to reduce the number of unnecessary prostate biopsies.
  2. Overview Patients who are indicated for prostate biopsy in suspicion of prostate cancer will be assigned to a control group and an intervention group under double blinded randomization.

    • Control group : Patients will undergo prostate biopsy guided by conventional ultrasonography (B mode, gray scale).
    • Experimental group : Patients will undergo prostate biopsy guided by shear wave elastography in addition to conventional ultrasonography.

A comparative statistical analysis of the two groups will be performed.

The study is planned to be conducted for 3 years, with 2 years for patient enrollment and 1 year of follow-up. Three hospitals will participate in the study to enroll 85 patients for each group and a total of 170 patients.

3. Inclusion and Exclusion criteria

  • Male patients with suspected prostate cancer must meet at least one of the following three criteria.

    1. PSA level over 4ng/dl
    2. Suspicious hard prostatic nodule on digital rectal examination.
    3. Hypoechoic lesion on ultrasound of the prostate suspicious for cancer.
  • Patients who (1) are less than 20 years old, (2) have a history of surgery on the prostate such as HoLEP, (3) have moderate cognitive impairment, or (4) have medical conditions precluding transrectal procedures such as rectal cancer are excluded from the study.

    4. Research method

  • Patients who wish to participate in this study and meet the inclusion/exclusion criteria are randomly assigned to the 2 groups as described above.
  • The biopsy results are checked one week after the procedure.

    • Patients confirmed to have prostate cancer are provided proper treatment according to generally accepted treatment methods.
    • Patients with negative biopsy results are followed according to general follow-up protocol for suspected prostate cancer patients. After 6 months from the biopsy the patients are re-evaluated and if cancer is still suspected based on PSA level or other clinical symptoms, prostate MRI or additional biopsy is be performed.
  • Patients are followed again after 12 months since the initial biopsy with identical methods from the 6 months follow-up protocol.

研究概览

研究类型

介入性

注册 (预期的)

170

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Woong Kyu Han
  • 电话号码:82-2-2228-2310
  • 邮箱:hanwk@yuhs.ac

学习地点

      • Seoul、大韩民国
        • Yonsei University Health System, Severance Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

21年 至 90年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

描述

Inclusion Criteria:

  1. PSA level over 4ng/dl
  2. Suspicious hard prostatic nodule on digital rectal examination.
  3. Hypoechoic lesion on ultrasound of the prostate suspicious for cancer.

Exclusion Criteria:

  1. Less than 20 years old
  2. History of surgery on the prostate such as HoLEP
  3. More than moderate cognitive impairment which limits understanding of the study
  4. Medical conditions precluding transrectal procedures such as rectal cancer

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Shear Wave Elastography Group
A 12-core template biopsy is planned as during a conventional prostate biopsy. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. The elasticity of each area is evaluated and region with the maximum Young's modulus value is selected and targeted for biopsy. Additional biopsy for suspicious lesions can be performed at the discretion of the practitioner.
有源比较器:Conventional ultrasonography Group
A conventional 12-core template biopsy is planned. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. Random biopsy of each area is performed. Additional biopsy of suspicious hypoechoic nodular lesions can be performed at the discretion of the practitioner.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Detection rate of prostate cancer
大体时间:The presence of prostate cancer on pathologic results is checked one to two weeks after the biopsy.
The number of subjects diagnosed with prostate cancer and the rate of detection by each group.
The presence of prostate cancer on pathologic results is checked one to two weeks after the biopsy.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Woong Kyu Han、Severance Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (预期的)

2021年5月3日

初级完成 (预期的)

2023年12月8日

研究完成 (预期的)

2024年2月1日

研究注册日期

首次提交

2021年4月6日

首先提交符合 QC 标准的

2021年4月7日

首次发布 (实际的)

2021年4月8日

研究记录更新

最后更新发布 (实际的)

2021年4月8日

上次提交的符合 QC 标准的更新

2021年4月7日

最后验证

2021年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅